Skip to main content

Table 1 Patient demographics and comorbidities

From: Postoperative outcomes of mepivacaine vs. bupivacaine in patients undergoing total joint arthroplasty with spinal anesthesia

 

Total Hip Arthroplasty

Total Knee Arthroplasty

Variable – n (%) or Avg. ± SD

Hyperbaric Bupivacaine (n=401)

Isobaric Bupivacaine (n=34)

Mepivacaine (n=232)

P-Value

Hyperbaric Bupivacaine (n=502)

Isobaric Bupivacaine (n=28)

Mepivacaine (n=131)

P-Value

Age

66.7 ± 11.4

65.3 ± 12.0

63.2 ± 9.6

0.001

68.9 ± 8.3

68.9 ± 8.2

66.1 ± 8.5

<0.001

BMI

29.4 ± 5.4

30.0 ± 6.0

28.5 ± 5.2

0.072

31.7 ± 5.3

31.3 ± 5.5

30.7 ± 4.9

0.061

Female

224 (55.9)

14 (41.2)

130 (56.0)

0.242

314 (62.5)

20 (71.4)

131 (50.0)

0.001

ASA ≥ 3

154 (38.4)

18 (52.9)

50 (21.6)

<0.001

225 (44.8)

10 (35.7)

82 (31.3)

0.001

CCI

3.15 ± 1.78

3.09 ± 1.73

2.48 ± 1.56

<0.001

3.35 ± 1.76

3.29 ± 1.27

2.91 ± 1.70

0.004

  1. P-Values <0.05 in bold
  2. BMI body mass index, ASA American Society of Anesthesiologists Score, CCI Charlson Comorbidity Index